Increasing the capacity and capability, and accessibility to the local population, of health-related omics research in Hull

提高赫尔健康相关组学研究的容量和能力以及当地居民的可及性

• 批准号: MR/X012301/1
• 负责人: Gavin Barlow
• 金额: $ 48.01万
• 依托单位: University of Hull
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FX012301%2F1
• 关键词: Increasing; capacity; capability; accessibility; local

The PromethION24 is a device used to analyse the nature of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in detail in clinical samples, and in bacteria, viruses or fungi identified from samples. The information generated by a PromethION24 can inform doctors and researchers about unique 'signals' within clinical samples, or the DNA/RNA of bacteria, viruses, or fungi, identified from such samples, which can help understanding of the processes that cause disease and develop new diagnostic tests, and/or inform about how an infection spreads within a population. This in turn can inform about how to control and/or improve the treatment of a condition. This so-called "genomics" technology (sometimes called "omics" which is a broader term for related research) has been used extensively in the COVID-19 pandemic. Hull University Teaching Hospitals (HUTH) has a rapidly expanding range of research, in areas of work the MRC is interested in funding. In collaboration with the University of Hull and Hull York Medical School, doctors at HUTH are applying "omics" to a range of clinical samples, which has resulted in local expertise using a related, but much lower throughput device called MinION. Capacity and capability to grow further is currently severely limited by this lower throughput technology. The PromethION24 will be housed in a laboratory based in the Daisy Building on the Castle Hill Hospital campus of HUTH. All co-applicants are based here, with Hull Royal Infirmary and the University of Hull close by, allowing easy transport of samples and close collaboration between clinical doctors and researchers. The PromethION24 delivers 24-times to 120-times more throughput, retains a low laboratory 'footprint', and overall reduces the cost of analysing each sample. High quality laboratory space in the Daisy Building at HUTH is dedicated to the careful storage and processing of patient samples for this type of research. Such analyses require powerful computers to analyse, interpret and store the produced data and this will be supported by the University of Hull VIPER supercomputer, which is one of the most powerful in the north of England, and supports current research. The Dept. of Research & Development, HUTH will oversee use and governance via a new "omics" committee, that will allow new research questions of notable local and national importance to be addressed with a focus initially on infection and wound related projects. Early projects will include studies of: the nature of bacteria in wounds and how they influence healing; the fungi on the skin and in the mouth of patients with acute leukaemia before, during and after they receive intensive chemotherapy and how this links to antifungal drug use and whether they develop an infection (linked to a NIHR funded trial, BioDriveAFS); bacteria that cause bloodstream infections in people who inject drugs compared to those who do not, and how this links to their infection and the spread of these bacteria in the community; the relationship between the nature of antibiotic resistant bacteria and how well a two antibiotic based therapy works against them in the laboratory; and the bacteria and unique 'signals' identified in the large joint fluid (e.g. knee) of patients with and without bacterial (septic) arthritis. Access will be available to other HUTH clinicians, and partner organisations, in keeping with our intended collaborative use, leading to data to support a programme of related future external funding applications, and a step-change in "omics" research locally. Importantly, the technology will increase research participation opportunities for local patients, who live in an area with high disease burden and that has been underserved by research activity. The award will also provide a platform for expanding "omics" education of local healthcare professionals and researchers, as well as facilitating increasing contributions to national genomics research projects.

PromethION24 是一款用于详细分析临床样本以及从样本中鉴定出的细菌、病毒或真菌中脱氧核糖核酸 (DNA) 和核糖核酸 (RNA) 性质的设备。 PromethION24 生成的信息可以向医生和研究人员提供有关临床样本中独特“信号”的信息，或者从此类样本中识别出的细菌、病毒或真菌的 DNA/RNA，这可以帮助了解导致疾病的过程并开发新的诊断测试，和/或了解感染如何在人群中传播。这反过来又可以告知如何控制和/或改善病情的治疗。这种所谓的“基因组学”技术（有时称为“组学”，是相关研究的更广泛术语）已在 COVID-19 大流行中广泛使用。赫尔大学教学医院 (HUTH) 的研究范围迅速扩大，MRC 有兴趣资助这些工作领域。 HUTH 的医生与赫尔大学和赫尔约克医学院合作，正在将“组学”应用于一系列临床样本，从而产生了使用相关但吞吐量低得多的设备 MinION 的本地专业知识。目前，这种较低吞吐量的技术严重限制了进一步增长的容量和能力。 PromethION24 将安装在 HUTH 城堡山医院校区 Daisy 大楼的实验室中。所有共同申请人都位于这里，赫尔皇家医院和赫尔大学就在附近，可以方便地运输样本，并让临床医生和研究人员之间进行密切合作。 PromethION24 的通量提高了 24 倍至 120 倍，保持了较低的实验室“占地面积”，并总体降低了分析每个样品的成本。 HUTH 黛西大楼的高质量实验室空间致力于为此类研究精心储存和处理患者样本。此类分析需要强大的计算机来分析、解释和存储产生的数据，这将得到赫尔大学 VIPER 超级计算机的支持，该超级计算机是英格兰北部最强大的计算机之一，并支持当前的研究。 HUTH 研究与开发部将通过一个新的“组学”委员会监督使用和治理，这将允许解决具有显着地方和国家重要性的新研究问题，最初重点关注感染和伤口相关项目。早期项目将包括以下方面的研究：伤口中细菌的性质及其如何影响愈合；急性白血病患者在接受强化化疗之前、期间和之后皮肤和口腔中的真菌情况，以及这与抗真菌药物的使用有何关系以及他们是否会发生感染（与 NIHR 资助的试验 BioDriveAFS 相关）；与不注射吸毒者相比，导致注射吸毒者血液感染的细菌，以及这与他们的感染和这些细菌在社区中的传播有何关系；抗生素耐药性细菌的性质与实验室中基于两种抗生素的疗法对它们的效果之间的关系；以及在患有或不患有细菌性（化脓性）关节炎的患者的大关节液（例如膝盖）中发现的细菌和独特的“信号”。根据我们预期的合作使用，其他 HUTH 临床医生和合作组织将可以访问，从而获得数据来支持相关的未来外部资金申请计划，以及本地“组学”研究的逐步变化。重要的是，该技术将增加当地患者参与研究的机会，这些患者生活在疾病负担高且研究活动服务不足的地区。该奖项还将提供一个平台，扩大当地医疗保健专业人员和研究人员的“组学”教育，并促进为国家基因组学研究项目做出更多贡献。